Disclaimer: We always strive to give accurate information with our blogs. For this article, we discovered we need to dig deeper into this topic to make sure we got it absolutely right. If you have any information on this content, please click here to visit our survey to update us.
We have positive news to share for people with diabetes who are on insulin and would like to use a CGM (Continuous Glucose Monitor)!
The Center for Medicare and Medicaid Services (CMS) is relaxing some of their stringent requirements for obtaining a CGM during the COVID-19 pandemic.
“CMS will not enforce certain clinical criteria in local coverage determinations that limit access to therapeutic continuous glucose monitors for beneficiaries with diabetes. As a result, clinicians will have greater flexibility to allow more of their diabetic patients to monitor their glucose and adjust insulin doses at home.”
CMS just announced they would not enforce certain clinical criteria for obtaining a CGM, insulin pump, or associated supplies during the pandemic. For example, in-clinic provider visits, certain lab tests like a C-peptide or antibody testing, and demonstrations of SMBG would not be mandatory.
This is huge for people with diabetes!
It would limit visits to hospitals, clinics, and labs and help reduce exposure to the coronavirus at these public facilities.
Since CGM’s and insulin pumps have the ability to transmit the collected data to a provider for a telehealth consult, providers can now use that data to review during telehealth visits. This can strengthen the relationship during COVID by allowing for data-driven insulin adjustments.
This is a win-win situation and we can hope that private insurance companies will follow the lead of CMS for the benefit of people with diabetes who use insulin.
Written by Catherine Cullinane RN, CDCES, our resident Tech Thursday Content Writer
Join Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, and ADCES 2020 Diabetes Educator of the year as she reviews these important topics. As Diabetes Specialists, we are tasked with taking a leadership role in technology and cardiovascular risk reduction. Dr. Isaacs will address these topics with clinical insight and expert knowledge during these two virtual courses.
Session 1 | CV Risk Management with Pharmacology and Intensive Insulin Therapy | Recorded & Ready for Viewing!
Session 2 | Continuous Glucose Monitoring and Insulin Pump Therapy | Recorded & Ready for Viewing!
$69 | Earn 4 CEs
These sessions are also included in our Virtual Conference.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
Accreditation: Diabetes Education Services is an approved provider by the California Board of Registered Nursing, Provider 12640, and Commission on Dietetic Registration (CDR), Provider DI002. Since these programs are approved by the CDR it satisfies the CE requirements for the CDCES regardless of your profession.*
The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.
April 14, 2021 – April 16, 2021
October 1 11:30 am – 12:45 pm
October 24 12:00 pm – December 7 2:15 pm
November 5 11:30 am – 12:45 pm